Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with excision repair cross-complementing-1 polymorphisms
Open Access
- 23 June 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (11) , 1854-1859
Abstract
Background: Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers following platinum therapy. Patients and methods: This multicenter study evaluated the activity of oxaliplatin and prolonged infusion of gemcitabine (‘GEMOX’ regimen) in recurrent NPC. Baseline blood samples were genotyped for the presence of ERCC1-118 gene polymorphisms. Results: Forty-two patients were recruited, of whom most (61%) had metastatic disease. Of the 40 patients evaluated for response, the respective overall response and disease control rates were 56.1% and 90.2%. At a median follow-up of 14.8 months, the respective median overall survival and time to progression were 19.6 months [95% confidence interval (CI) = 12.8–22 months] and 9 months (95% CI = 7.3–10 months). Grade 3–4 toxic effects were uncommon. The distribution of ERCC1-118 genotypes from 29 patients was C/C (n = 17, 40.5%), C/T (n = 10, 23.8%) and T/T (n = 2, 4.8%). No differences in survival or response rates were found between genotypes. Conclusions: GEMOX is active in the treatment of recurrent NPC. Detection of single-nucleotide gene polymorphisms from genomic DNA in peripheral blood is feasible in NPC and further studies are warranted.Keywords
This publication has 26 references indexed in Scilit:
- Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directionsCancer Science, 2008
- Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 ChemotherapyJournal of Clinical Oncology, 2007
- Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary ResultsJournal of Clinical Oncology, 2005
- ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal CancerClinical Cancer Research, 2005
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinomaOral Oncology, 2005
- Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and TaxaneOncology, 2004
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated typeAnnals of Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000